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Tacrolimus (Prograf™-FK506) has been commercially available 
since June, 1994, for use as an immunosuppressive agent. It has 
thus far been approved only for patients undergoing liver 
transplantation,l although it has been used both clinically and 
experimentally in virtually all other organ or cell transplant 
settings. 2- 11 It has been used successfully in renal transplant 
recipients, both as a primary immunosuppressive agent 12- 25 and as a 
rescue agent,25-27 and several reports have suggested that it is more 
efficacious than cyclosporine-based therapy. 17,18,23 
In this report, we will present an update of our experience 
with tacrolimus as the primary immunosuppressive agent, and as a 
rescue agent, in renal transplant recipients. In addition, we will 
discuss the use of tacrolimus in kidney/pancreas transplantation, 
and in our program of bone marrow augmentation. With increasing 
follow-up, it is becoming clear that tacrolimus is a superior 
immunosuppressive agent. 
PRIMARY THERAPY 
Adults 
After an initial experience demonstrated comparable efficacy 
between tacrolimus and cyclosporine, but with an improved secondary 
profile in tacrolimus-treated patients (lower steroid and 
antihypertensive medication requirements, and lower cholesterol 
levels) ,12-14 a prospective, randomized trial was begun in August, 
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1991, com.paring two tacrolimus-based regimens, with and without 
azathioprine .15-18 Induction antilymphocyte therapy was not used. 
397 cases were entered into this trial, which ended in December, 
1993. Analysis was by intention-to-treat, with no patients 
censored. With a mean follow-up of 33 ± 10 months, overall 1 and 
3 actuarial patient survival was 95% and 92%, with no difference 
between the two groups (Figure 1). Overall 1 and 3 actuarial graft 
survival was 89% and 80% (Table 1), with a significantly worse 3 
year outcome in the triple therapy than in the double therapy 
group, 76% versus 84% (p=.031). When first cadaver grafts were 
analyzed, overall 1 and 3 actuarial graft survival was 91% and 82%, 
wi th no difference between the two groups. Subgroup analysis 
revealed that patients with delayed graft function or steroid-
resistant rej ection were at increased risk for graft loss. In 
addition, recipients of kidneys from donors over 60 years of age 
had worse outcomes (Table 2). Black recipients, retransplant 
recipients, and sensitized patients did not have statistically 
worse outcomes, nor did recipients of female donor or pediatric en 
bloc kidneys. 
At most recent follow-up, the mean serum creatinine was 1.9 ± 
1.5 mg/dl, and 69% of successfully transplanted patients had been 
taken off steroids; 38% were off antihypertensive medications 
(Table 3). 
A half-life analysis was performed, and the projected half-
life for all cadaver recipients was 11.4 ± 2.0 years; for first 
3 
cadaver recipients, it was 11.9 ± 2.5 years. 
These data have continued to demonstrate the efficacy and 
superiority of tacrolimus in adult renal transplant recipients, but 
have called into question the utility of azathioprine as a third 
agent. A subsequent randomized trial assessing the efficacy of one 
week of low dose cyclophosphamide is currently being analyzed, and 
a new randomized trial of tacrolimus and steroids with and without 
mycophenolate mofeti128 is currently in progress. 
Pediatrics 
Between December 17, 1989, and June 30, 1995, sixty-eight 
pediatric patients underwent 69 renal transplantations and received 
tacrolimus-based therapy, again without induction antilymphocyte 
therapy (this analysis excludes children undergoing concomitant or 
previous liver transplantation). The mean age was 10.3 ± 5.0 years 
(range 0.7 17.5); 17 (24.6%) children were undergoing 
retransplantation, and 6 (8.7 %) had a PRA of 40% or higher. 39 
(57%) transplants were with cadaveric kidneys, and 30 (43%) were 
with living donors. With a mean follow-up of 32 ± 20 months, 
overall 1 and 4 year actuarial patient survival was 100% and 96% 
(Figure 2). The one patient who died lost her kidney to 
noncompliance and died on dialysis 17 months after allograft 
nephrectomy. Overall 1 and 4 year actuarial graft survival was 99% 
and 85%. 
The mean serum creatinine was 1.2 ± 0.8 mg/dl (Table 4). 73% 
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of successfully transplanted children have been weaned off 
prednisone. Growth in the pre-adolescent children off steroids has 
been particularly gratifying. 
The incidence of rejection was 49%, and antilymphocyte therapy 
was required in 6% of children. There is a suggestion that the 
incidence of rejection has been less over the past 18 months, as 
more experience with tacrolimus has been acquired. 
An early concern with our pediatric patients receiving 
tacrolimus was the incidence of Epstein-Barr virus associated post-
transplant lymphoprolifera ti ve disorder (PTLD). 24,25,29 Between 
December 17, 1989, and December 31, 1992, five (17%) cases were 
seen in the first 29 recipients, and although no child died or lost 
his/her kidney, temporary sensation of immunosuppression and a 
prolonged course of antiviral therapy with gancyclovir were 
required. Beginning in 1993, a conscious change in 
immunosuppressive management was implemented, with aggressive 
tapering of both tacrolimus and steroids beginning 6-8 weeks after 
transplantation. The incidence of PTLD in the 40 patients 
transplanted since January 1, 1993, has decreased to 5% (2 cases); 
in both cases, the PTLD resolved with medical therapy as outlined 
above. There has also been one case of a late PTLD showing a 
Burkitt's lymphoma-like histology 46 months after transplantation, 
after a 50% increase in the tacrolimus dosage was instituted. This 
patient responded to aggressive chemotherapy. 
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RESCUE THERAPY 
Prior to FDA approval, a significant experience was acquired 
in Pittsburgh with tacrolimus as a rescue agent for renal 
transplant recipients who had failed conventional therapyKO~OT Most 
of these patients were transplanted at other centers. Over 200 
patients with refractory acute rejection were eventually converted, 
and while a detailed analysis of this group is still in progress, 
the overall success rate was comparable to the 74% originally 
reported in the first 77 patients. The previous analysis had 
indicated that, even in cases of patients who arrived on dialysis, 
successful rescue was possible in 50% of cases. 27 
KIDNEY/PANCREAS TRANSPLANTATION 
Between July 4, 1994, and September 30, 1995, 43 simultaneous 
kidney/pancreas transplantations were performed under tacrolimus-
based immunosuppression. As in the kidney alone patients, 
induction antilymphocyte therapy was not given. With a median 
follow-up of 6 months, all patients are alive, with 95% renal 
allograft survival and 79% pancreas allograft survival (Table 5). 
Steroid tapering has been possible, and 8 (19%) patients have had 
steroids completely withdrawn. 
KIDNEY/BONE MARROW 
Based on the observation that extremely long-term graft 
survival was associated with systemic microchimerism,30-33 a program 
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of combined, simultaneous kidney/bone marrow transplantation was 
begun in December, 1992, with the goal of augmenting chimerism. 34 - 37 
Thirty-six cases were transplanted by October 31, 1994. 38 Patients 
received 3-5 x 108 unmodified bone marrow cells/kg at the 
conclusion of the kidney transplant. Immunosuppression was with 
tacrolimus and steroids. 
transplant 
Seven patients receiving a 
kidney/pancreas were also given azathioprine. 
Radiation, cytoreduction, or induction antilymphocyte therapy were 
not given. With a mean follow-up of 11.1 ± 5.8 months, all 
patients were alive and 33 (92%) patients had functioning renal 
allografts (Table 6). A group of 20 patients who did not received 
bone marrow were studied as controls. Patient and graft survival, 
quali ty of allograft function, and the incidence of rej ection, 
delayed function, or cytomegalovirus were not different between the 
two groups. Graft versus host disease was not seen in any patient. 
Chimerism was detected in 97% of the kidney/bone marrow group, and 
64% of the control group (p=.02). These early results suggest that 
bone marrow augmentation is safe and is associated with reasonable 
patient and graft survival and routine augmentation of chimerism. 
The long-term consequences of the increased chimerism await further 
follow-up. 
DISCUSSION 
As more experience has been acquired with tacrolimus in renal 
transplant recipients, it is becoming increasingly clear that 
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better outcomes are being seen, both in the form of higher short-
term graft survival rates, longer projected half-lives, and steroid 
withdrawal in a majority of recipients. These outcomes have lead 
to the routine use of tacrolimus in our renal and pancreas 
transplant recipients. Current strategies call for a pre-operative 
oral dose of 0.15 mg/kg and a continuous intravenous infusion of 
0.05-0.075 mg/kg/24 hours, beginning in the recovery room. Oral 
tacrolimus is begun at a dose of 0.15 mg/kg twice daily, after 
which the intravenous tacrolimus is quickly tapered. The target 
levels vary over time; we aim for levels of 20-25 ng/ml (whole 
blood IMX) for the first 2 weeks after transplantation, tapering 
down to 15-20 ng/ml by 1 month, 10-15 ng/ml by 3 months, and 5-12 
ng/ml chronically, although many long-term patients do well with 
chronic levels between 3-5 ng/ml. In the ideal circumstance, 
steroids are decreased from 20 to 15 mg/d 3 weeks after 
transplantation, and then by 2.5 mg decrements to 10 mg/d by 2 
months. Tapering by 2.5 mg/month continues until steroids are 
discontinued altogether. The doses are proportionally lower for 
pediatric recipients. 
The toxicities of tacrolimus are well-known and include 
nephrotoxicity, neurotoxicity, and diabetogenicityKP~4R 
similar to those seen with cyclosporine 46-s1 and are 
They are 
largely 
reversible with dosage reduction and steroid tapering. The 
infectious complications associated with tacrolimus also appear to 
be qualitatively and quantitatively similar to those seen with 
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cyclosporine. 14 • 17 
A continuing problem with tacrolimus is a moderately high 
incidence of rejection of approximately 50%. While most rejections 
are steroid-responsive, those requiring antilymphocyte therapy are 
associated with relatively poor outcomes. It is hoped that the 
addition of mycophenolate mofetil as a third agent will be 
associated with less rejection and equally good or perhaps even 
better graft survival. For now, however, tacrolimus appears to 
represent an advance in immunosuppression for renal transplant 
recipients, and should be considered to be the agent of choice. 
SUMMARY 
1. Tacrolimus is a superior immunosuppressive agent in patients 
undergoing renal transplantation. In adults, the 1 and 3 year 
actuarial patient survival was 95% and 92%, and the 1 and 3 
year actuarial graft survival was 89% and 80%. For first 
cadaver kidneys, the 1 and 3 year actuarial graft survival was 
91% and 82%, with a projected half-life of 11.9 years. 69% 
of successfully transplanted patients were able to be weaned 
off steroids. 
9 
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2. In pediatric patients, the 1 and 4 year actuarial patient 
survival was 100% and 96%, 
graft survival was 99% 
and the 1 and 4 year actuarial 
and 85%. 73% of successfully 
transplanted children were weaned off steroids. 
3. Tacrolimus was also useful as a rescue agent, with an initial 
success rate of 74%. 
4. Tacrolimus has been used successfully in kidney/pancreas 
transplantation, with 100% patient, 95% kidney, and 79% 
pancreas graft survival. 
5. Tacrolimus should be considered to be the immunosuppressive 
agent of choice in renal transplantation. 
10 
Figure 1 
Figure 2 
Renal Transplantation Under Tacrolimus - Patient & 
Graft Survival in Adults. 
Pediatric Renal Transplantation Under Tacrolimus -
Patient and Graft Survival 
11 
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Tacrolimus/Prednisone vs. Tacrolimus/Azathioprine/Prednisone 
Table 1 Actuarial Survival N=397 
FK/Pred FK/Aza/Pred Oiiera.ll 
Patient 
1 year 97% 94% 95% 
2 year 95% 91% 93% 
3 year 94% 90% 92% 
p=NS 
Graft 
1 year 90% 88% 89% 
2 year 86% 81% 84% 
3 year 84% 76% 80% 
p=.031 
Graft-First Cadaver 
1 year 90% 91% 91% 
2 year 85% 83% 84% 
3 year 84% 80% 82% 
p=NS 
22 
Tacrolimus/Prednisone vs. Tacrolimus/Azathioprine/Prednisone 
Table 2 Actuarial Graft Survival - Subgroup Analysis 
Immediate Function 
Delayed Graft Function 
No Rejection 
Rejection - Steroids 
Rejection - OKT3/ATG 
Donor S 60 years 
>60 years 
En Bloc 
Other Cadaver 
Female Donor 
Male Donor 
Black Recipients 
Non-Black 
First Transplant 
Retransplant 
PRA <40% 
PRA ~4M% 
1 year 
95% 
78% 
91% 
92% 
71% 
91% 
74% 
84% 
89% 
90% 
88% 
88% 
89% 
91% 
83% 
89% 
87% 
2 year 
90% 
72% 
87% 
86% 
57% 
86% 
65% 
84% 
83% 
83% 
84% 
76% 
85% 
85% 
80% 
84% 
83% 
23 
3 year 
86% 
69% 
87% l l 
I NS I 
p 
0.00001 
80% J I 0.00001 
53% J 
83% 0.0001 
62% 
84% NS 
79% 
80% NS 
81% NS 
70% NS 
82% 
82% NS 
75% NS 
81% NS 
78% NS 
Tacrolimus/Prednisone VS. Tacrolimus/Azathioprine/Prednisone 
Table 3 
FK/Pred FK/Aza/Pred Overall 
S. Creatinine (mg/ dl) 1.9±1.0 1. 9±1. 8 1.9 ± 1.5 
Off Steroids 70% 68% 69% 
Off Antihypertensive 
Medications 39% 36% 38% 
24 
Table 4 Pediatric Recipients - Actuarial Survival 
Patient 
Graft 
S. Creatinine (mg/dl) 
Off Steroids 
1 year 
100% 
99% 
1.2 ± 0.8 
73% 
25 
4 year 
96% 
85% 
n=69 
Table 5 Kidney - Pancreas Transplantation 
Patient Survival 
Renal Allograft Survival 
Pancreas Allograft Survival 
100% 
95% 
79% 
26 
n=43 
Table 6 Kidney/Bone Marrow Transplantation 
n=36 n=20 p 
K/BM Control 
Patient Survival 100% 90% NS 
Graft Survival 92% 85% NS 
Chimerism 97% 64% 0.02 
• 
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